Kenji Watanabe

Kenji Watanabe

Auto-generated profile, based on publicly available information

Kenji Watanabe

Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama , Toyama

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MKMasahiro Kishi
Masahiro Kishi
FHFumihito Hirai
Fumihito Hirai
NTNoritaka Takatsu
Noritaka Takatsu
THTakashi Hisabe
Takashi Hisabe
YTYasumichi Takada
Yasumichi Takada
THTadakazu Hisamatsu
Tadakazu Hisamatsu
Many clinical trials have been conducted for inflammatory bowel disease (IBD), so various clinical indices (CIs) and endoscopic indices (EIs) have also been evaluated. However, recently, with the progress of IBD management, review of established indices from previous studies, and establishment of new indices, the landscape of the use of indices in clinical trials have changed. We investigated the number and frequency of the indices adapted in recent clinical trials for ulcerative colitis (CI and EI) and Crohn’s disease (CI, EI, index related to magnetic resonance imaging, index for evaluating patient-reported outcomes, and health-related quality of life). Based on the results, we selected representative indices and further reviewed their content and characteristics. Moreover, various definitions, including clinical and endoscopic response or remission, have been described by means of representative indices in clinical trials.

9 November 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
HYHironori Yamamoto
Hironori Yamamoto
TYTomonori Yano
Tomonori Yano
AAAkihiro Araki
Akihiro Araki
MEMotohiro Esaki
Motohiro Esaki
KOKazuo Ohtsuka
Kazuo Ohtsuka
HIHaruhiro Inoue
Haruhiro Inoue

4 March 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
TYTakayuki Yamamoto
Takayuki Yamamoto
HNHiroshi Nakase
Hiroshi Nakase
KWKenji Watanabe
Kenji Watanabe
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
NTNoritaka Takatsu
Noritaka Takatsu
TKTomoe Kazama
Tomoe Kazama
Background and Aims: Perianal lesion is a refractory phenotype of Crohn’s disease [CD] with significantly diminished quality of life. We evaluated the clinical characteristics of perianal lesions in newly diagnosed CD patients and the impact of perianal lesions on the quality of life in Japanese patients with CD. Methods: Patients newly diagnosed with CD after June 2016 were included between December 2018 and June 2020 from the Inception Cohort Registry Study of Patients with CD [iCREST-CD]. Results: Perianal lesions were present in 324 [48.2%] of 672 patients with newly diagnosed CD; 71.9% [233/324] were male. The prevalence of perianal lesions was higher in patients aged <40 years vs ≥40 years, and it decreased with age. Perianal fistula [59.9%] and abscess [30.6%] were the most common perianal lesions. In multivariate analyses, male sex, age <40 years and ileocolonic disease location were significantly associated with a high prevalence of perianal lesions, whereas stricturing behaviour and alcohol intake were associated with low prevalence. Fatigue was more frequent [33.3% vs 21.6%] while work productivity and activity impairment-work time missed [36.3% vs 29.5%] and activity impairment [51.9% vs 41.1%] were numerically higher in patients with than those without perianal lesions. Conclusions: At the time of CD diagnosis, approximately half of the patients had perianal lesions; perianal abscesses and perianal fistulas were the most common. Young age, male sex, disease location and behaviour were significantly associated with the presence of perianal lesions. The presence of perianal lesion was associated with fatigue and impairment of daily activities. Clinical trials registry: University Hospital Medical Information Network Clinical Trials Registry System [UMIN-CTR, UMIN000032237].

1 April 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
TMTakayuki Matsumoto
Takayuki Matsumoto
THTadakazu Hisamatsu
Tadakazu Hisamatsu
HNHiroshi Nakase
Hiroshi Nakase
SMSatoshi Motoya
Satoshi Motoya
NYNaoki Yoshimura
Naoki Yoshimura
AYAtsushi Yoshida
Atsushi Yoshida
We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy versus combination with azathioprine for patients with Crohn's disease (CD) who were naive to biologics and thiopurines. We performed a subanalysis of data from this study to evaluate factors associated with endoscopic response and mucosal healing in study participants. We compared simple endoscopic scores for CD between patients with moderate to severe active CD randomly assigned groups that received adalimumab monotherapy (n = 85) or adalimumab in combination with azathioprine (n = 91), from June 2011 to June 2014 in Japan. We evaluated associations of simple endoscopic scores for CD with clinical factors and trough levels of adalimumab. Ultimately, 135 patients at Week 26 and 139 patients at Week 52 from 44 referral sites were analyzed for the present investigation. The odds for endoscopic response were significantly higher in the combination group than in the monotherapy group at Week 26 (odds ratio [OR], 2.12; 95% confidence interval [CI], 1.04-4.32) but not at Week 52 (OR, 1.50; 95% CI, 0.77-2.94). The odds of mucosal healing did not differ significantly between groups at Weeks 26 or 52. Simple endoscopic scores for CD at Week 0 was significantly associated with mucosal healing at Week 26 (OR, 0.80; 95% CI, 0.72-0.90) and at Week 52 (OR, 0.91; 95% CI, 0.84-0.99). Higher adalimumab trough level at Week 26 associated with mucosal healing at Week 52 (OR, 1.34; 95% CI, 1.14-1.58; P for trend = .001) and was significantly higher in patients with endoscopic response than in patients without endoscopic response at Weeks 26 and 52 (P < .001). In a post hoc analysis of data from a randomized controlled trial of patients with moderate to severe CD, we found that adalimumab in combination with azathioprine increased trough levels of adalimumab. Higher trough levels of adalimumab associated with endoscopic response and mucosal healing at Weeks 26 and 52. UMIN registration No: 000005146.

23 September 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
SFSatomi Furukawa
Satomi Furukawa
TMTsunekazu Mizushima
Tsunekazu Mizushima
RNRyo Nakaya
Ryo Nakaya
MSMari Shibata
Mari Shibata
TYTakayoshi Yamaguchi
Takayoshi Yamaguchi
KFKitaro Futami
Kitaro Futami
Previous studies conducted in Europe suggested that darvadstrocel, a suspension of expanded, allogeneic, adipose-derived, mesenchymal stem cells, is safe and effective for treatment-refractory complex perianal fistulas in patients with Crohn’s disease. The aim of this study was to evaluate the efficacy and safety of darvadstrocel for the treatment of complex perianal fistulas in Japanese adults with Crohn’s disease. This is a phase 3, open-label, single-arm study conducted at nine sites in Japan. Adult patients with non-active or mildly active Crohn’s disease and complex perianal fistulas received a single 24-mL intralesional injection of darvadstrocel [120 × 106 cells]. The primary endpoint was combined remission (clinically confirmed closure of all treated external openings that were draining at screening, and absence of collections >2 cm, [confirmed by magnetic resonance imaging] among treated fistulas) at Week 24. Between March 6, 2019 and February 1, 2021, 22 patients received darvadstrocel and completed the 52-week follow-up. The proportion of patients achieving combined remission at Week 24 was 59.1% (95% confidence interval [CI], 38.5–79.6). The effect was maintained at Week 52, with 68.2% [95% CI, 48.7–87.6] of patients achieving combined remission. Treatment-related adverse events included: one [4.5%] patient with worsening of Crohn’s disease and diarrhoea, and one [4.5%] patient with blood bilirubin increase. No new safety findings were identified in this study. The efficacy and tolerability of darvadstrocel in Japanese adult patients with treatment-refractory complex perianal fistulas in Crohn’s disease were similar to those observed in the previous European study. ClinicalTrials.gov number, NCT03706456.

31 August 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MUMotoi Uchino
Motoi Uchino
HIHiroki Ikeuchi
Hiroki Ikeuchi
KHKEISUKE Hata
KEISUKE Hata
TMTomohiro Minagawa
Tomohiro Minagawa
YHYUKI HORIO
YUKI HORIO
MWMamoru Watanabe
Mamoru Watanabe